Stockscreener 앱 받기
1.915
1.79%
-0.035
시간 외 거래:
1.94
0.025
+1.31%
전일 마감가:
$1.95
열려 있는:
$1.93
하루 거래량:
3,155
Relative Volume:
0.30
시가총액:
$32.22M
수익:
$22.06M
순이익/손실:
$-30.94M
주가수익비율:
-0.8549
EPS:
-2.24
순현금흐름:
$-26.70M
1주 성능:
-7.93%
1개월 성능:
-8.37%
6개월 성능:
-67.87%
1년 성능:
-31.48%
1일 변동 폭
$1.915
$1.94
1주일 범위
$1.915
$2.08
52주 변동 폭
$1.88
$7.67
Casi Pharmaceuticals Inc Stock (CASI) Company Profile
CASI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CASI
Casi Pharmaceuticals Inc
|
1.915 | 32.22M | 22.06M | -30.94M | -26.70M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Casi Pharmaceuticals Inc Stock (CASI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-05-18 | 개시 | BTIG Research | Buy |
| 2021-04-26 | 개시 | Mizuho | Buy |
| 2020-10-23 | 개시 | Oppenheimer | Outperform |
| 2016-09-22 | 개시 | Maxim Group | Buy |
| 2015-10-29 | 재개 | H.C. Wainwright | Buy |
| 2015-06-23 | 개시 | H.C. Wainwright | Buy |
모두보기
Casi Pharmaceuticals Inc 주식(CASI)의 최신 뉴스
CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia - ACCESS Newswire
StockNews.com Begins Coverage on CASI Pharmaceuticals (NASDAQ:CASI) - Defense World
CASI Pharmaceuticals (NASDAQ:CASI) Coverage Initiated by Analysts at StockNews.com - Defense World
CASI Pharmaceuticals, Inc.Ordinary Shares (NQ: CASI - FinancialContent
Brokers Issue Forecasts for CASI Q1 Earnings - Defense World
StockNews.com Initiates Coverage on CASI Pharmaceuticals (NASDAQ:CASI) - Defense World
HC Wainwright Has Lowered Expectations for CASI Pharmaceuticals (NASDAQ:CASI) Stock Price - Defense World
CASI stock touches 52-week low at $1.88 amid market challenges - Investing.com
CASI Pharmaceuticals Moves to Arbitration in Dispute with Acrotech - TipRanks
CASI receives updated buyout offer for China operations - The Pharma Letter
CASI Pharma Stock Rises On $20M Buyout Offer From CEO For China Business Operations: Retail Remains Extremely - Asianet Newsable
CASI Pharma stock hits 52-week low at $1.9 amid market challenges - Investing.com Australia
CASI Pharma Stock Rises On $20M Buyout Offer From CEO For China Business Operations: Retail Remains Extremely Bullish - MSN
CASI Pharmaceuticals receives buyout proposal from CEO By Investing.com - Investing.com South Africa
CASI Pharma stock hits 52-week low at $1.9 amid market challenges By Investing.com - Investing.com South Africa
CASI Pharmaceuticals Acquires Precision Autoimmune Therapeutics - TipRanks
Casi Pharmaceuticals Signs Agreement To Acquire Equity Interests In Precision Autoimmune Therapeutics - marketscreener.com
CASI Pharmaceuticals Receives Updated Acquisition Proposal for China Operations - TipRanks
CASI Pharmaceuticals receives buyout proposal from CEO - Investing.com
CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company - ACCESS Newswire
CASI Pharma's CEO Makes Strategic $20M Bid for Entire China BusinessKey Pipeline Assets Included - Stock Titan
CASI Pharmaceuticals Full Year 2024 Earnings: US$2.56 loss per share (vs US$2.02 loss in FY 2023) - Yahoo
Short Interest in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Declines By 15.0% - Defense World
CASI Pharmaceuticals Reports 2024 Financial Results and Strategic Developments - TipRanks
Press Release Distribution & PR Platform - ACCESS Newswire
CASI Delivers Record Q4 Growth: FDA Clearance Powers Next-Gen Treatment Pipeline - Stock Titan
CASI Pharmaceuticals (NASDAQ:CASI) Earns Hold Rating from Analysts at StockNews.com - Defense World
CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Shares Lagging The Industry But So Is The Business - Simply Wall St
CASI Pharmaceuticals (NASDAQ:CASI) Now Covered by StockNews.com - The AM Reporter
CASI Pharma stock hits 52-week low at $2.04 amid market challenges - Investing.com
CASI Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
CASI Pharmaceuticals (NASDAQ:CASI) Coverage Initiated at StockNews.com - Defense World
Hypoxia Treatment Market to Witness Substantial Growth by 2031 | - openPR
CASI Pharmaceuticals (NASDAQ:CASI) Research Coverage Started at StockNews.com - Defense World
Multiple Myeloma Clinical and Non-Clinical Studies, Key - openPR
CASI Pharmaceuticals Secures Interim Relief in Juventas Dispute - TipRanks
This CASI Pharmaceuticals Insider Increased Their Holding By 65% Last Year - Yahoo Finance
Critical Comparison: Biora Therapeutics (NASDAQ:BIOR) versus CASI Pharmaceuticals (NASDAQ:CASI) - Defense World
Critical Contrast: Evolus (NASDAQ:EOLS) and Nuvectis Pharma (NASDAQ:NVCT) - Defense World
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) Secures EU Patent for FHAB Platform Technology - Defense World
Multiple Myeloma Pipeline 2024: FDA Approvals, Therapies, - openPR
Casi Pharmaceuticals Inc (CASI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):